Floatz logo

Byetta

Fatty Liver Disease

University of Colorado, DenverPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Metformin
Leiden University Medical Center
Phase 4BBB
Alpha Tocopherol
Yuen Kah Hay
Phase 4BB
Dolutegravir
Fundacion SEIMC-GESIDA
Phase 4BB
Raltegravir
Helsinki University Central Hospital
Phase 4BB
Empagliflozin
Seoul National University Bundang Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Byetta is also rated in:

polycystic ovary syndromeDormant
B
Indicative ·
61 / 100
View asset →
diabetes mellitusDormant
B
Indicative ·
60 / 100
View asset →
obesity disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →